Ralista 60 contains raloxifene, a selective estrogen receptor modulator (SERM) that is primarily used to help prevent and treat osteoporosis in postmenopausal women. It may also help reduce the risk of invasive hormone receptor-positive breast cancer in certain postmenopausal women who have osteoporosis or are considered to have a higher risk of developing breast cancer. Raloxifene works by blocking the effects of estrogen in breast tissue. Since some breast cancers rely on estrogen to grow, reducing estrogen's activity in the breast may lower the chance of these cancer cells developing. However, Ralista 60 is not used to treat existing breast cancer and does not prevent all types of breast cancer.

Women who may benefit from Ralista 60 are those who have been assessed by their healthcare provider as having an increased risk of invasive breast cancer based on factors such as age, family history, or certain medical conditions. Before prescribing the medication, doctors carefully evaluate the potential benefits and risks for each individual. Regular breast screenings, including mammograms and clinical breast examinations, remain essential while taking Ralista 60 because no medication completely eliminates the risk of breast cancer. Patients should also report any unusual breast changes to their healthcare provider promptly.

Ralista 60 works best as part of a comprehensive approach to breast health rather than as a standalone preventive measure. Maintaining a healthy weight, exercising regularly, limiting alcohol consumption, avoiding smoking, and following recommended screening schedules can further support breast cancer risk reduction. Like all prescription medications, Ralista 60 may cause side effects and is not suitable for everyone, particularly individuals with a history of blood clots. It should only be used under medical supervision, with regular follow-up appointments to monitor its safety and effectiveness.